adequate counseling. The adoption of a contraceptive method and the number of pregnancies were not different between the two groups. The history of use of embryotoxic/teratogenic drugs was associated with a higher frequency of adequate counseling (79.6% vs 41.5%, p=0.001). According to the patients, adequate counseling was given by the rheumatologist in 75.5% of the cases (p=0.001). Objectives: The aim of this study was to examine the association between IR and disease activity, disease characteristics, drug exposure and subclinical atherosclerosis in patients with SLE. Methods: Cross-sectional study that encompassed 87 SLE patients and 82 sex-matched controls. IR by homeostatic model assessment (HOMA2), insulin, C-peptide serum levels and lipid profile were assessed in both groups. Activity (SLEDAI), severity (Katz) and damage (SLICC) scores, carotid intima-media thickness (cIMT) and carotid plaques (ultrasound) were assessed in SLE patients. A multivariable regression analysis, adjusted for IR related factors, was performed to evaluate the differences between groups in IR indexes and, in SLE patients, the interrelation between IR and disease activity/characteristics as well as subclinical atherosclerosis. Results: Median disease duration was 16 years (IQR 9-21). Body mass index, abdominal circumference, hypertension or dyslipidemia did not differ between groups. According to the SLEDAI score, 40% of patients were in no activity, while 32, 21, 18 and 1% were in mild, moderate, high and very high activity respectively. HOMA-IR-C-peptide (beta coefficiente 0.53, [95% CI 0.25-0.82], p=0.00) was increased in SLE patients when compared to controls, as well as HOMA %B C peptide levels (beta coef. 35, 95% CI 18-52, p=0.00). Similarly, insulin sensitivity estimated through HOMA-S% was inferior in SLE patients (-beta coef. -37, 95% CI -63-11, p=0.01).This diferences remained significant even after adjustment for IR related factors. SLICC damage index was clearly asociated with IR indexes; higher index values were related to higher HOMA-IR-C-peptide (beta coef. 37, [95% CI 16-57], p=0.00) and lower HOMA-S% levels (beta coef. 30%, [95% CI -47-14], p=0.00). Katz severity index showed correlation with HOMA-IR-C-peptide (beta coef.-5, [95% CI -11-0], p=0.04). These associations remained significant after adjustment for age, gender, smoking, hypertension and dyslipidemia, and, in relation with the SLICC index, also after adjustment for prednisone intake. SLEDAI activity index was not related to IR indexes. The use of prednisone was positively associated with HOMA-IR both when considered binary (beta coef 47, [95% CI 31-63], p=0.00) and continous (beta coef 2 [95% CI 0-5] per mg, p=0.03). Hydroxycloroquine (or other drugs) use was not associated with IR indexes, neither were disease duration, antiDNA titers and complement serum levels. Carotid plaques were found in 20% of the SLE patients. The presence of carotid plaques was correlated with a higher HOMA-IR-C-peptide ], p=0.02), and a higher cIMT value was associated with a lower HOMA-IR-S%>C-peptide Background: Proteinuria is the principal urinary biomarker for the screening of Lupus nephritis (LN) and for monitoring disease progression. 24-hour urine collection has been the foundation for monitoring disease activity in patients with LN, but collections are often inaccurate and inconvenient. The European League Against Rheumatism and American College of Rheumatology have recommended the urine protein/creatinine ratio (UPCR) for use in management of LN.
FRI0281 UTILITY OF MORNING SAMPLE OF URINE PROTEIN/CREATININE RATIO FOR ASSESSMENT OF PROTEINURIA IN PATIENTS WITH LUPUS NEPHRITIS
H. Zhang, J. Liang, B. Hua, L. Sun. Department of Rheumatology and Immunology, The Affiliated Drum Tower Hospital of Nanjing University Medical School, Nanjing, China Background: Proteinuria is the principal urinary biomarker for the screening of Lupus nephritis (LN) and for monitoring disease progression. 24-hour urine collection has been the foundation for monitoring disease activity in patients with LN, but collections are often inaccurate and inconvenient. The European League Against Rheumatism and American College of Rheumatology have recommended the urine protein/creatinine ratio (UPCR) for use in management of LN.
Objectives: We aimed to evaluate the diagnostic accuracy of the morning sample of UPCR compared with 24-hour urine collection for the detection of proteinuria and to determine the UPCR for different proteinuria ranges in patients with LN. Methods: Three hundred and thirty seven LN patients were enrolled. The correlation between the UPCR in the morning spot urine samples and urinary protein excretion in the 24-hour collections was examined using the Pearson correlation test. The best cutoffs for UPCR predicting a 24-hour protein excretion were determined with the receiver operating characteristic curve (ROC). Results: It was found a good positive correlation between the UPCR and 24-hour protein excretion, with a correlation coefficient (r) of 0.891 (Fig 1) . The best cutoff which gave the maximum area under the curve was 0.44 for 0.5 g, 0.92 for 1.0 g, 2.21 for 2.0 g, 2.70 for 3.0 g, 3.49 for 4.0 g and 4.59 for 5.0g.
Conclusions:
The UPCR can be used as a screening test as a good predictor for proteinuria of LN patients. Also, UPCR is a valuable tool with which to monitor disease progression. 
